Supplement claims citing "degrees of normality" are not disease claims, attorney suggests.
This article was originally published in The Tan Sheet
Executive Summary
DIETARY SUPPLEMENT CLAIMS CITING "DEGREES OF NORMALITY" are not necessarily disease statements, D.C. attorney Anthony Young (Piper & Marbury) suggested at a forum on dietary supplements in Washington, D.C. April 30. In commentary on FDA's April 29 proposed rule on structure/function claims, Young suggested industry focus attention on the provision that designates as inappropriate for supplements statements claiming an effect on an "abnormality" of the body, including, for example, symptoms associated with menopause.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning